Published in Hepatitis Weekly, August 1st, 2005
According to a study from Germany, "The aim of this multicenter-study was to evaluate the progression-free survival, response rate, and toxicity of the combination of bendamustine and rituximab in patients with mantle cell or low-grade lymphomas in first to third relapse or refractory to previous treatment. A total of 245 courses (median, 4 courses per patient) were administered to 63 patients."
"Bendamustine was given at a dose of 90 mg/m2 as a 30-minute infusion on days 1 and 2, combined with 375 mg/m2 rituximab on day 1, for a maximum of 4 cycles every 4...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.